Exclusive Group Transitions Leadership Team for Next Stage of Growth
Exclusive Group, the global value-added services and technologies (VAST) group, today announced Andy Travers as its new SVP Worldwide Sales and Marketing. The ex-Fortinet and RSA executive will be responsible for leading the next phase of Exclusive’s growth strategy to build the world’s biggest specialist VAD in cybersecurity and cloud transformation with targeted revenues of $10bn over the next 5 years.
The appointment coincides with the news that Exclusive Group’s current COO, Barrie Desmond, has decided to step down at the end of 2018 to pursue other interests. Affectionately dubbed ‘Disruptive Desmond’, he has played a key role in developing Exclusive’s go-to-market proposition, market positioning and sales growth over the last 7 years.
Andy Travers is a 25-year veteran of IT channel sales excellence, achieving success at reseller, VAD and global vendor organisations. As SVP of Worldwide Sales and Marketing, Travers will be responsible for steering Exclusive to unprecedented revenues, heading up strategic alliances with major vendors, developing key relationships with GSIs and taking executive control of global services. His previous roles include SVP and VP Sales positions on both sides of the Atlantic for Fortinet, as well as VP EMEA stints at F5 Networks and, most recently, RSA Security.
Commenting on the changes Olivier Breittmayer, Exclusive Group’s CEO said, “Following our recent investment from Permira funds we set ourselves high expectations for executing against our new growth strategy. Andy has the skills and experience necessary to contribute to us achieving our goals and understands our unique culture and values having been in the orbit of Exclusive working with our vendors and channel partners for many years. We are delighted to have him onboard.
“Barrie’s decision to stand down at the end of the year is totally respected by myself and the board. We’ve worked well together these past 7 years, architecting and driving the growth of this business and telling the story only we can tell. It’s been a great journey together and we wish him all the best for the future.”
Commenting on his appointment Andy Travers said, “Exclusive has earned a worldwide reputation for doing what no other VAD has been able to do – delivering genuine value-add at scale. I’m joining at a pivotal time for the business as we commit to exploiting the global opportunities around cybersecurity and cloud transformation to reach another step-change in growth. The investors and management team have developed a winning strategy and now it’s all about the execution. I’m delighted to be joining and really looking forward to helping achieve the next phase of growth.”
Desmond and Travers will work closely together over the next few months to ensure a smooth transition.
Commenting on his decision to leave Exclusive at the end of the year, COO Barrie Desmond said, “My work here is done. We’ve had an incredible journey and built a VAD that continues to disrupt, grow sales at an extraordinary rate and expand its footprint at an astonishing tempo. Along the way we’ve reinvented Distribution and redefined value. But now it’s time for the next generation of disruptors to take on the challenge of growing the world’s largest specialist VAD.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181004005109/en/
Contact information
Cohesive
Jon Bawden
+44 (0) 1291 626200
exclusivegroup@wearecohesive.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
